AU2024208533A1 - Dopamine d3/d2 receptor modulating compounds - Google Patents

Dopamine d3/d2 receptor modulating compounds

Info

Publication number
AU2024208533A1
AU2024208533A1 AU2024208533A AU2024208533A AU2024208533A1 AU 2024208533 A1 AU2024208533 A1 AU 2024208533A1 AU 2024208533 A AU2024208533 A AU 2024208533A AU 2024208533 A AU2024208533 A AU 2024208533A AU 2024208533 A1 AU2024208533 A1 AU 2024208533A1
Authority
AU
Australia
Prior art keywords
dopamine
modulating compounds
receptor modulating
receptor
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024208533A
Other languages
English (en)
Inventor
Szilvia BODNÁRNÉ DÉAK
István BORZA
Bálint Menczinger
János ÉLES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of AU2024208533A1 publication Critical patent/AU2024208533A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2024208533A 2023-01-11 2024-01-10 Dopamine d3/d2 receptor modulating compounds Pending AU2024208533A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11
US63/479,530 2023-01-11
PCT/IB2024/000026 WO2024150068A2 (en) 2023-01-11 2024-01-10 Dopamine d3/d2 receptor modulating compounds

Publications (1)

Publication Number Publication Date
AU2024208533A1 true AU2024208533A1 (en) 2025-07-10

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024208533A Pending AU2024208533A1 (en) 2023-01-11 2024-01-10 Dopamine d3/d2 receptor modulating compounds

Country Status (16)

Country Link
US (2) US12168007B1 (cg-RX-API-DMAC7.html)
EP (1) EP4400495A1 (cg-RX-API-DMAC7.html)
JP (2) JP7686096B2 (cg-RX-API-DMAC7.html)
KR (2) KR102921799B1 (cg-RX-API-DMAC7.html)
CN (2) CN122427144A (cg-RX-API-DMAC7.html)
AR (1) AR131577A1 (cg-RX-API-DMAC7.html)
AU (1) AU2024208533A1 (cg-RX-API-DMAC7.html)
CL (2) CL2025002035A1 (cg-RX-API-DMAC7.html)
CO (1) CO2025010725A2 (cg-RX-API-DMAC7.html)
GE (1) GEAP202516807A (cg-RX-API-DMAC7.html)
IL (1) IL321654A (cg-RX-API-DMAC7.html)
JO (1) JOP20250164A1 (cg-RX-API-DMAC7.html)
MX (1) MX2025008101A (cg-RX-API-DMAC7.html)
PE (1) PE20260287A1 (cg-RX-API-DMAC7.html)
TW (1) TW202432139A (cg-RX-API-DMAC7.html)
WO (1) WO2024150068A2 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026153547A1 (zh) * 2025-01-20 2026-07-23 上海则正医药科技股份有限公司 D3/d2受体部分激动剂及制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
JP5732453B2 (ja) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Nh酸性化合物のプロドラッグ
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
US12617759B2 (en) 2019-10-29 2026-05-05 Shanghai Hansoh Biomedical Co., Ltd. Modifier of four-membered ring derivative, preparation method and application thereof
KR102947882B1 (ko) 2019-11-05 2026-04-03 상하이 한서 바이오메디컬 컴퍼니 리미티드 벤조티오펜 유도체 조절제, 그의 제조 방법 및 그의 용도

Also Published As

Publication number Publication date
CL2025002035A1 (es) 2025-10-03
CN120569367A (zh) 2025-08-29
EP4400495A1 (en) 2024-07-17
CO2025010725A2 (es) 2025-08-29
KR102921799B1 (ko) 2026-02-04
JP2024098972A (ja) 2024-07-24
PE20260287A1 (es) 2026-02-10
US12168007B1 (en) 2024-12-17
TW202432139A (zh) 2024-08-16
US20250049786A1 (en) 2025-02-13
KR20260019592A (ko) 2026-02-10
WO2024150068A3 (en) 2024-08-22
GEAP202516807A (en) 2025-08-25
AR131577A1 (es) 2025-04-09
JP7686096B2 (ja) 2025-05-30
JP2025122072A (ja) 2025-08-20
MX2025008101A (es) 2025-08-01
CL2026000558A1 (es) 2026-06-05
JOP20250164A1 (ar) 2025-07-10
IL321654A (en) 2025-08-01
KR20240112213A (ko) 2024-07-18
WO2024150068A2 (en) 2024-07-18
CN122427144A (zh) 2026-07-21

Similar Documents

Publication Publication Date Title
AU2022297367B2 (en) Diacylglyercol kinase modulating compounds
AU2022297373B2 (en) Diacylglyercol kinase modulating compounds
AU2022298639B2 (en) Diacylglyercol kinase modulating compounds
AU2022299051B2 (en) Diacylglyercol kinase modulating compounds
EP4380936A4 (en) PYRAZOLOPYRIDINONE COMPOUNDS
AU2024225939A1 (en) Mc2r modulator compounds
IL321654A (en) Compounds for regulating dopamine D3/D2 receptors
CA3278215A1 (en) Dopamine d3/d2 receptor modulating compounds
HK40093361A (en) Gpr52 modulator compounds
HK40085862A (en) Indole compounds as androgen receptor modulators
HK40102920A (en) Substituted indole compounds
CA3275670A1 (en) Inorganic compounds
CA3282363A1 (en) Mc2r modulator compounds
HK40128989A (en) Mc2r modulator compounds
HK40104480A (en) Estrogen receptor modulators
CA3310209A1 (en) Pyrazolopiperazine compounds
CA3305167A1 (en) Survivin-targeted compounds
CA3295507A1 (en) Compounds
CA3295511A1 (en) Pyrrolopyridine compounds for the treatment of mental illnesses
CA3283976A1 (en) Compounds
AU2023903954A0 (en) Compounds
CA3275025A1 (en) Compounds
AU2023902054A0 (en) Compounds
AU2023902053A0 (en) Compounds
AU2023900353A0 (en) Compounds